SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is currently the subject of intense community debate, with bulls highlighting the company's substantial power infrastructure and AI data center optionality, while bears remain focused on the potential impact of a large capital raise. Investors are actively tracking the progress of site energization and the potential for new hyperscaler contracts to drive the next leg of growth amid the sector's broader volatility.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is currently trending as shareholders and analysts debate whether the stock represents a deep-value opportunity or a persistent value trap given its low valuation multiples and ongoing share buybacks. The community is actively discussing the lack of communication from the new CEO, potential for M&A activity, and the stock's frustratingly sluggish performance despite recent strategic partnership news and stable free cash flow.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is currently a focal point for investors as they navigate a series of major contract wins, including counter-drone defense deployments for the 2026 FIFA World Cup and border security programs. While bulls point to aggressive growth and institutional support, the community remains divided and highly sensitive to the company's ongoing share dilution and its performance relative to broader market volatility.

Maulcoin

Maulcoin is trending as the community celebrates the return of its official ticker and ramps up efforts to secure exchange listings and technical charting. Supporters are actively rallying around the coin's grassroots growth and "dark side" branding, positioning it as an organic alternative to the rapid pump-and-dump cycles common in the current memecoin market.

NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.

Nano Nuclear Energy Inc.

Nano Nuclear Energy is trending as investors react to a series of strategic milestones, including a new feasibility study for a major Texas power hub and the continued expansion of its microreactor development pipeline. The community is actively debating the company's long-term commercialization timeline and the broader role of advanced nuclear technology in meeting the surging electricity demands of AI data centers.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as the community eagerly awaits updates on the Clarity Act, which investors believe will solidify the token's status as a digital commodity and provide the regulatory framework needed for wider adoption. While some participants are actively accumulating positions in anticipation of a potential rally, the community remains deeply divided, with vocal debates highlighting ongoing frustration over long-term price action and a lack of official communication.

BARK, Inc. is a dog-centric company, engaged in making products, services, and content for dogs. It operates through the Direct to Consumer and Commerce segments. The Direct to Consumer segment is composed of subscription-based products delivered on a monthly basis. The Commerce segment refers to the sale of BARK products in retail stores and other e-tailers. The company was founded by Matt M. Meeker, Henrik Werdelin, and Carly Strife in 2012 and is headquartered in New York, NY.

BARK Inc - Ordinary Shares - Class A

BARK Inc

BARK is experiencing intense downward pressure as investors grow increasingly skeptical of management's turnaround efforts following a series of disappointing performance indicators. Community sentiment is deeply divided, with some traders viewing the current depressed market valuation as an opportunistic entry point, while many long-term shareholders express frustration over the lack of communication, management's handling of the capital structure, and the looming threat of a reverse split.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies (PLTR) is experiencing heightened volatility following a public endorsement from President Trump on Truth Social, which intensified the ongoing debate between market participants focused on defense-sector momentum and those skeptical of the stock's valuation. While the political spotlight has spurred speculative buying and tactical trading, investors remain sharply divided over the potential long-term impact of competitive pressure from Anthropic and broader software sector repricing.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as investors closely monitor its upcoming earnings report, with community sentiment buoyed by recent analyst upgrades, positive momentum following the termination of a potential Warner Bros. Discovery deal, and strategic pricing power initiatives. Traders are actively debating the stock's ability to sustain support above key technical levels, with many viewing it as a resilient defensive play in an uncertain macro environment.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian is currently facing heavy institutional de-risking and a broader sector-wide selloff, driven by investor fears that AI-native tools and agentic models could disrupt traditional enterprise software workflows. While some market participants view the stock as deeply oversold and a long-term value opportunity due to its entrenched position in development workflows, the community remains divided, with many actively trading it as a high-conviction short amid ongoing downward price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Moderate Buy" by Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six analysts that are presently covering the company, Marketbeat reports...

Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Wall Street Zen

Wall Street Zen raised Aclaris Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

Aclaris Therapeutics (NASDAQ:ACRS) Trading Up 10.2% - What's Next?

Aclaris Therapeutics (NASDAQ:ACRS) Shares Up 10.2% - Time to Buy...

Aclaris Therapeutics' (ACRS) Outperform Rating Reaffirmed at Wedbush

Wedbush restated an "outperform" rating and issued a $8.00 price objective on shares of Aclaris Therapeutics in a report on Tuesday...

Aclaris Therapeutics (NASDAQ:ACRS) Shares Pass Below 50 Day Moving Average   - Should You Sell?

Aclaris Therapeutics (NASDAQ:ACRS) Stock Crosses Below 50-Day Moving Average - Here's What Happened...

Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains?

Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Q1 EPS Estimate for Aclaris Therapeutics Raised by Analyst

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Analysts at HC Wainwright boosted their Q1 2026 EPS estimates for shares of Aclaris Therapeutics in a research note issued on Thursday, March 19th. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will post earning...

Aclaris Therapeutics (NASDAQ:ACRS) Receives Buy Rating from HC Wainwright

HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of Aclaris Therapeutics in a research report on Thursday...

HC Wainwright Has Positive Forecast for ACRS FY2026 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities researchers at HC Wainwright increased their FY2026 earnings per share estimates for Aclaris Therapeutics in a research report issued...

Research Analysts Offer Predictions for ACRS FY2027 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities researchers at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of Aclaris Therapeutics in a note...

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Current Price	$4.04
Prev Close	$4.08
Open	$4.08
Dividend Yield	0.00%
50-Day Moving Average	$3.50
Beta	1.16
Avg. Volume	2.75M
PE Ratio	-7.63

52-Week High	$4.89
52-Week Low	$1.08
Market Capitalization	$492.03M
EPS (Annual)	-$0.5297
Price to Book	4.72
Revenue Per Employee	$107,205.48

ACRS
Aclaris Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACRS News

ACRSAclaris Therapeutics Inc